8 Questions on Diabetes Drugs for Cardioprotection

News
Slideshow

Slideshow

Cardioprotective effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) have been reported in a number of high-profile, landmark clinical trials.

Take this quick quiz to test your knowledge of key findings.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces / image credit courtesy of Mayo Clinic

CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces

Grace Halsey
January 16th 2025
Article

"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Atumelnant Demonstrates Rapid and Sustained Biomarker Reduction in Phase 2 Trial in Adults with Congenital Adrenal Hyperplasia / image credit ©Sebastian Kaulitzki/stock.adobe.com

Atumelnant Demonstrates Rapid and Sustained Biomarker Reduction in Phase 2 Trial in Adults with Congenital Adrenal Hyperplasia

Grace Halsey
January 10th 2025
Article

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Mobile App Shows Promise for Hypertension Management: Daily Dose / image credit: ©New Africa/AdobeStock

Mobile App Shows Promise for Hypertension Management: Daily Dose

Sydney Jennings
January 9th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

Grace Halsey
January 8th 2025
Article

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

© 2025 MJH Life Sciences

All rights reserved.